drugset / Trial / NCT05435729
A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study is an open-label of single transdermal dose of DSP-9632P to evaluate the dopamine release derived from levodopa in brain, and a randomized, double-blind, placebo-controlled, 2-way crossover of multiple transdermal doses of DSP-9632P to evaluate the safety and tolerability in patients with levodopa-induced dyskinesia in Parkinson's disease.
Timeline
- Start
- 2022-05-31
- Primary completion
- 2022-11-30
- Completion
- 2022-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DSP-9632P | Unknown | 27.5 mg | Other |
| Subject | DSP-9632P | Unknown | 55 mg | Other |
| Subject | DSP-9632P | Unknown | 82.5 mg | Other |
| Background | Levodopa formulation | Unknown | — | — |